To the question of the dualism of neutrophils' role in the processes of carcinogenesis, as well as the possibility of cell application for malignant neoplasm therapy

Neutrophils are phagocytic, myeloid-type leukocytes that are the most common myeloid cells in human blood, normally comprising 65 to 80% of all circulating leukocytes. Over the years of research into these cells, more and more evidence has emerged demonstrating the functional plasticity of neutrophils and their ambiguous role in tumor development. Similar to the M1/M2 classification of macrophages, the N1/N2 paradigm can be applied to neutrophils, where N1 neutrophils exhibit tumor-suppressive properties, while N2 neutrophils promote tumor development and suppression of immunity. An important natural feature of neutrophils is their mobility and ability to overcome physical barriers, which is why these cells, as well as their vesicles and membranes, can be used to deliver therapeutic drugs to tumor cells. Moreover, neutrophils themselves can be activated and mobilized to fight tumors. This review describes the current state of research into the role of neutrophils in carcinogenesis, as well as possible approaches to the use of these cells and their derivatives as delivery systems for therapeutic drugs for the treatment of malignant neoplasms.